Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma

NCT00504101 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Temporarily closed to accrual pending availablity of drug.

Conditions

Multiple Myeloma and Plasma Cell Neoplasm

Interventions

DRUG: Arsenic trioxide
DRUG: Bortezomib
DRUG: Melphalan
BIOLOGICAL: Autologous hematopoietic stem cell transplantation

Sponsor

University of Miami